The Association of Radiation Dose-Fractionation and Immunotherapy Use With Overall Survival in Metastatic Melanoma Patients

医学 黑色素瘤 倾向得分匹配 分馏 内科学 比例危险模型 剂量分馏 免疫疗法 放射治疗 肿瘤科 生存分析 癌症 胃肠病学 核医学 癌症研究 有机化学 化学
作者
Shang-Jui Wang,Sachin R. Jhawar,Zorimar Rivera‐Núñez,Ann W. Silk,Jaemin Byun,Eric D. Miller,Dukagjin Blakaj,Rahul R. Parikh,Joseph Weiner,Sharad Goyal
出处
期刊:Cureus [Cureus, Inc.]
被引量:8
标识
DOI:10.7759/cureus.8767
摘要

ObjectiveMetastatic melanoma patients often receive palliative radiotherapy (RT) and immunotherapy (IT).However, the immunological interplay between RT dose-fractionation and IT is uncertain, and the optimal treatment strategy using RT and IT in metastatic melanoma remains unclear.Our main objective was to examine the effect of RT dose-fractionation on overall survival (OS). MethodsUsing the National Cancer Database (NCDB), we classified metastatic melanoma patients who received palliative RT into two dose-fractionation groups -conventionally fractionated RT (CFRT; <5 Gy/fraction) and hypofractionated RT (HFRT: ≥5 Gy/fraction) -with or without IT.Survival analysis was performed using the Cox regression model, Kaplan-Meier method, and propensity-score matching (PSM). ResultsA total of 5,281 metastatic melanoma patients were included, with a median follow-up of 5.9 months.The three-year OS was highest in patients who received HFRT+IT [37.3% (95% CI: 31.1-43.5)]compared to those who received HFRT alone [19.0%(95% CI: 16.2-21.9)],)], or CFRT alone [8.6% (95%CI: 7.6-9.7);p<0.0001].The magnitude of OS benefit with the use of IT was greater in those who received HFRT (18.3%) compared with those who received CFRT (9.0%) (p<0.0001).The addition of IT to HFRT, compared to CFRT, was associated with greater OS benefit in patients treated with RT to the brain and soft tissue/visceral (STV) sites.On PSM analysis, HFRT+IT was associated with improved three-year OS compared to other treatments. ConclusionMetastatic melanoma patients who received HFRT+IT was associated with the greatest OS benefit.Our findings warrant further prospective evaluation as to whether higher RT dose-per-fraction improves clinical outcomes in metastatic melanoma patients receiving IT.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
维生素发布了新的文献求助10
1秒前
butterfly发布了新的文献求助10
3秒前
豆豆完成签到 ,获得积分10
4秒前
范先生完成签到,获得积分10
7秒前
2222222完成签到,获得积分10
7秒前
Hello应助bulingbuling采纳,获得10
7秒前
蜡笔小新完成签到,获得积分10
10秒前
希望天下0贩的0应助小王采纳,获得10
10秒前
赘婿应助lh采纳,获得10
11秒前
11秒前
科研通AI2S应助butterfly采纳,获得10
12秒前
大模型应助butterfly采纳,获得10
12秒前
14秒前
做个梦给你完成签到,获得积分10
14秒前
学霸宇大王完成签到 ,获得积分10
14秒前
甜蜜的楷瑞完成签到,获得积分10
15秒前
魏煜佳完成签到,获得积分10
16秒前
Lc完成签到,获得积分10
16秒前
三伏天完成签到,获得积分10
16秒前
清图完成签到,获得积分10
16秒前
英姑应助简单采纳,获得10
16秒前
爱喝牛奶的大兔子完成签到 ,获得积分20
17秒前
18秒前
18秒前
潇湘雪月完成签到,获得积分10
19秒前
迎南完成签到,获得积分10
19秒前
懒癌晚期完成签到,获得积分10
20秒前
20秒前
初夏微凉发布了新的文献求助10
20秒前
20秒前
21秒前
22秒前
乐乐应助科研通管家采纳,获得10
23秒前
深情安青应助科研通管家采纳,获得10
23秒前
赘婿应助科研通管家采纳,获得10
23秒前
英姑应助科研通管家采纳,获得10
23秒前
田様应助科研通管家采纳,获得10
23秒前
所所应助科研通管家采纳,获得10
23秒前
英俊的铭应助科研通管家采纳,获得10
23秒前
烟花应助科研通管家采纳,获得10
23秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
Research on Disturbance Rejection Control Algorithm for Aerial Operation Robots 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038388
求助须知:如何正确求助?哪些是违规求助? 3576106
关于积分的说明 11374447
捐赠科研通 3305798
什么是DOI,文献DOI怎么找? 1819322
邀请新用户注册赠送积分活动 892672
科研通“疑难数据库(出版商)”最低求助积分说明 815029